Citadel Advisors
LEXX icon

Citadel Advisors’s Lexaria Bioscience LEXX Stock Holding History

Citadel Advisors’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.9K Buy
10,463
+9,562
+1,061% +$104K ﹤0.01% 12781
2026
Q1 		$10.5K Buy
+901
New +$9.81K ﹤0.01% 12750
2024
Q2 		– Sell
-1,057
Closed -$57.6K – 14932
2024
Q1 		$57.6K Sell
1,057
-914
-46% -$34.9K ﹤0.01% 12042
2023
Q4 		$37K Buy
+1,971
New +$38.1K ﹤0.01% 12078
2023
Q1 		– Sell
-1,245
Closed -$45.8K – 15140
2022
Q4 		$45.8K Sell
1,245
-413
-25% -$14.8K ﹤0.01% 12244
2022
Q3 		$61K Sell
1,658
-201
-11% -$8.59K ﹤0.01% 11488
2022
Q2 		$83K Buy
+1,859
New +$74.7K ﹤0.01% 11568
2021
Q2 		– Sell
-994
Closed -$84K – 14073
2021
Q1 		$84K Buy
+994
New +$87.4K ﹤0.01% 12607

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Citadel Advisors's LEXX Position: Q2 2026 in Review

Citadel Advisors increased its Lexaria Bioscience (LEXX) stake by 1,061% in Q2 2026, buying an estimated $104K and bringing the position to 10,463 shares worth $87.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12781.

Citadel Advisors first reported a position in LEXX in Q1 2021 and has held it in 8 quarters since. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Citadel Advisors held 10,463 shares of Lexaria Bioscience worth $87.9K as of Q2 2026.
  • Citadel Advisors bought 9,562 Lexaria Bioscience shares in Q2 2026, an estimated $104K.
  • Lexaria Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12781 holding.
  • Citadel Advisors first reported a position in Lexaria Bioscience in Q1 2021 and has held it in 8 quarters since.
  • 29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.